Travere Therapeutics Q2 Adj EPS $(0.77) Beats $(1.16) Estimate, Sales $59.70M Beat $53.93M Estimate
Portfolio Pulse from bharat@benzinga.com
Travere Therapeutics reported Q2 adjusted EPS of $(0.77), beating the estimate of $(1.16) by 33.62%. The company also reported sales of $59.70M, surpassing the estimate of $53.93M by 10.69%. However, this represents an 18.46% decrease in EPS and a 10.21% increase in sales compared to the same period last year.
August 04, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics reported better than expected Q2 results, with both EPS and sales beating estimates. However, the company's EPS decreased compared to last year.
Travere Therapeutics reported better than expected Q2 results, which is generally a positive signal for investors. However, the decrease in EPS compared to last year might raise concerns about the company's profitability, potentially limiting the positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100